-
公开(公告)号：US20220380299A1
公开(公告)日：2022-12-01
申请号：US17538217
申请日：2021-11-30
Applicant: ModernaTX, Inc.
Inventor： Kerry E. BENENATO , Mark CORNEBISE
IPC: C07C229/12 , C07C271/20 , C07C279/12 , C07C279/28 , C07C279/32 , C07D233/72 , C07D249/04 , C07D263/20 , C07D265/33 , C07D271/06 , C07D271/10 , C07D207/27 , C07D277/38 , C07C275/14 , C07C279/24 , C07C311/05 , C07C229/16 , C07C335/08 , C07C233/36 , C07C235/10 , C07C255/24 , C07F9/09 , A61K47/54 , A61K47/69 , A61K9/00 , A61K9/127 , C07C233/72 , C07C263/20 , A61K9/16 , A61K38/18 , A61K48/00 , C07K14/505 , C07C227/16 , A61K9/51 , A61K31/7105 , A61K38/17 , C07C227/18
Abstract: The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
-
2.发明申请公开(公告)号：US20230000773A1
公开(公告)日：2023-01-05
申请号：US17761863
申请日：2020-09-18
Applicant: ModernaTX, Inc.
Inventor： Kerry E. BENENATO , Mark CORNEBISE , Edward HENNESSY , Andrew MCKENZIE
IPC: A61K9/127 , C07D285/10 , C07D207/456 , C07D237/22 , C07D233/88 , C07D249/14 , C07D271/08 , C07D239/22 , C07D241/20 , C07C237/10 , C07D209/14 , C07D231/56 , C07C311/05 , C07F5/02 , C07F9/36 , C07D319/12 , C07D307/68 , C07D239/38 , C07D285/18 , A61K31/7105
Abstract: The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
-
3.发明申请公开(公告)号：US20210087135A1
公开(公告)日：2021-03-25
申请号：US17025779
申请日：2020-09-18
Applicant: ModernaTX, Inc.
Inventor： Kerry E. BENENATO , Mark CORNEBISE , Edward HENNESSY , Ellalahewage S. KUMARASINGHE
IPC: C07C229/24 , A61K48/00 , A61K9/127 , A61K47/54 , A61K31/713
Abstract: The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
-
公开(公告)号：US20190314292A1
公开(公告)日：2019-10-17
申请号：US16382423
申请日：2019-04-12
Applicant: ModernaTX, Inc.
IPC: A61K9/51 , C07C229/24 , A61K48/00 , A61K38/18
Abstract: The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
-
公开(公告)号：US20190016669A1
公开(公告)日：2019-01-17
申请号：US16148822
申请日：2018-10-01
Applicant: ModernaTX, Inc.
Inventor： Kerry E. BENENATO , Mark CORNEBISE
IPC: C07C229/12 , C07C227/16 , C07C271/20 , A61K9/00 , A61K9/127 , C07C227/18 , A61K48/00 , A61K38/17 , A61K31/7105 , A61K9/51 , A61K9/16 , A61K47/69 , A61K47/54 , C07K14/505 , A61K38/18 , C07F9/09 , C07C255/24 , C07C235/10 , C07C233/36 , C07C335/08 , C07C229/16 , C07C311/05 , C07C279/24 , C07C275/14 , C07D277/38 , C07D207/27 , C07D271/10 , C07D271/06 , C07D265/33 , C07D263/20 , C07D249/04 , C07D233/72 , C07C279/32 , C07C279/28 , C07C279/12
CPC classification number: C07C229/12 , A61K9/0019 , A61K9/0043 , A61K9/0073 , A61K9/127 , A61K9/1271 , A61K9/1272 , A61K9/1617 , A61K9/1641 , A61K9/5123 , A61K9/5146 , A61K31/7105 , A61K38/1725 , A61K38/1816 , A61K47/543 , A61K47/6911 , A61K48/00 , A61K48/0033 , A61K48/005 , C07C227/16 , C07C227/18 , C07C229/16 , C07C233/36 , C07C235/10 , C07C255/24 , C07C271/20 , C07C275/14 , C07C279/12 , C07C279/24 , C07C279/28 , C07C279/32 , C07C311/05 , C07C335/08 , C07C2601/02 , C07C2601/04 , C07C2601/14 , C07C2601/18 , C07D207/27 , C07D233/72 , C07D249/04 , C07D263/20 , C07D265/33 , C07D271/06 , C07D271/10 , C07D277/38 , C07F9/091 , C07K14/505
Abstract: The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
-
Patent Agency Ranking
公开(公告)号：US20220402965A1
公开(公告)日：2022-12-22
申请号：US17277829
申请日：2019-09-19
Applicant: ModernaTX, Inc.
Inventor： Kerry BENENATO , Mark CORNEBISE , Edward J. HENNESSY
IPC: C07J7/00 , A61K9/51 , C07J17/00 , C07J43/00 , C07J33/00 , C07J41/00 , C07J9/00 , C07J21/00 , C07J71/00 , C07J31/00 , C07J51/00 , A61K31/7115 , A61K38/46 , A61K31/7105 , A61K47/10 , A61K47/24 , A61K47/28 , A61K48/00
Abstract: The invention relates to compositions and methods for the preparation, manufacture, and therapeutic use of compositions comprising mRNA and a lipid nanoparticle comprising a compound of the invention and an ionizable lipid.
-
公开(公告)号：US20190314291A1
公开(公告)日：2019-10-17
申请号：US16262758
申请日：2019-01-30
Applicant: ModernaTX, Inc.
Inventor： Gilles BESIN , Luis BRITO , Stephen G. HOGE , Edward HENNESSY , Mark CORNEBISE , Kerry BENENATO , Staci SABNIS , Michael W. DANNEMAN
IPC: A61K9/51 , C07K14/525 , A61P35/00 , C07K14/705 , A61K39/245
Abstract: The disclosure features immune cell delivery lipid nanoparticle (LNP) compositions that allow for enhanced delivery of agents, e.g., nucleic acids, such as therapeutic and/or prophylactic RNAs, to immune cells, in particular T cells, as well as B cells, dendritic cells and monocytes. The LNPs comprise an effective amount of an immune cell delivery potentiating lipid such that delivery of an agent by an immune cell delivery LNP is enhanced as compared to an LNP lacking the immune cell delivery potentiating agent. Methods of using the immune cell delivery LNPs for delivery of agents, e.g., nucleic acid delivery, for protein expression, for modulating immune cell activity and modulating immune responses are also disclosed.
-
8.发明公开公开(公告)号：US20240226026A1
公开(公告)日：2024-07-11
申请号：US18551704
申请日：2022-03-23
Applicant: ModernaTX, Inc.
Inventor： Kerry E. BENENATO , Mark CORNEBISE , Edward HENNESSY , Mohindra SEEPERSAUD , Michael W. DANNEMAN
IPC: A61K9/51 , C07C233/36 , C07C233/62 , C07C233/78 , C07C311/32 , C07D205/04 , C07D207/16 , C07D213/74 , C07D231/12 , C07D271/07 , C07D285/10 , C07D307/24 , C07D309/08
CPC classification number: A61K9/5123 , C07C233/36 , C07C233/62 , C07C233/78 , C07C311/32 , C07D205/04 , C07D207/16 , C07D213/74 , C07D231/12 , C07D271/07 , C07D285/10 , C07D307/24 , C07D309/08
Abstract: The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
-
公开(公告)号：US20240124388A1
公开(公告)日：2024-04-18
申请号：US18467190
申请日：2023-09-14
Applicant: ModernaTX, Inc.
Inventor： Kerry E. BENENATO , Mark CORNEBISE
IPC: C07C229/12 , A61K9/00 , A61K9/127 , A61K9/16 , A61K9/51 , A61K31/7105 , A61K38/17 , A61K38/18 , A61K47/54 , A61K47/69 , A61K48/00 , C07C227/16 , C07C227/18 , C07C229/16 , C07C233/36 , C07C233/72 , C07C235/10 , C07C255/24 , C07C263/20 , C07C271/20 , C07C275/14 , C07C279/12 , C07C279/24 , C07C279/28 , C07C279/32 , C07C311/05 , C07C335/08 , C07D207/27 , C07D233/72 , C07D249/04 , C07D263/20 , C07D265/33 , C07D271/06 , C07D271/10 , C07D277/38 , C07F9/09 , C07K14/505
CPC classification number: C07C229/12 , A61K9/0019 , A61K9/0043 , A61K9/0073 , A61K9/127 , A61K9/1272 , A61K9/1617 , A61K9/1641 , A61K9/5123 , A61K9/5146 , A61K31/7105 , A61K38/1725 , A61K38/1816 , A61K47/543 , A61K47/6911 , A61K48/0033 , A61K48/005 , C07C227/16 , C07C227/18 , C07C229/16 , C07C233/36 , C07C233/72 , C07C235/10 , C07C255/24 , C07C263/20 , C07C271/20 , C07C275/14 , C07C279/12 , C07C279/24 , C07C279/28 , C07C279/32 , C07C311/05 , C07C335/08 , C07D207/27 , C07D233/72 , C07D249/04 , C07D263/20 , C07D265/33 , C07D271/06 , C07D271/10 , C07D277/38 , C07F9/091 , C07K14/505 , A61K9/1271 , A61K48/00 , C07C2601/02 , C07C2601/04 , C07C2601/14 , C07C2601/18
Abstract: The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
-
公开(公告)号：US20230027864A1
公开(公告)日：2023-01-26
申请号：US17747618
申请日：2022-05-18
Applicant: ModernaTX, Inc.
Inventor： Gilles BESIN , Luis BRITO , Stephen G. HOGE , Edward HENNESSY , Mark CORNEBISE , Kerry BENENATO , Staci SABNIS , Michael W. DANNEMAN
IPC: A61K9/51 , A61P35/00 , A61K39/245 , C07K14/525 , C07K14/705
Abstract: The disclosure features immune cell delivery lipid nanoparticle (LNP) compositions that allow for enhanced delivery of agents, e.g., nucleic acids, such as therapeutic and/or prophylactic RNAs, to immune cells, in particular T cells, as well as B cells, dendritic cells and monocytes. The LNPs comprise an effective amount of an immune cell delivery potentiating lipid such that delivery of an agent by an immune cell delivery LNP is enhanced as compared to an LNP lacking the immune cell delivery potentiating agent. Methods of using the immune cell delivery LNPs for delivery of agents, e.g., nucleic acid delivery, for protein expression, for modulating immune cell activity and modulating immune responses are also disclosed.
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.031 seconds)
